Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Type 2 Diabetes Mellitus (T2DM)
100%
Metformin
62%
Insulin
40%
Diabetes
32%
Glycemic Control
26%
Insulin Resistance
25%
Glucagon-like
24%
Type 2 Diabetic Patients
22%
Glucose-lowering Drugs
21%
Obesity
19%
Hyperglycemia
18%
Insulin Release
18%
Dapagliflozin
17%
Diabetic
16%
Antihyperglycemic
15%
Glucose-dependent Insulinotropic Polypeptide
14%
Insulin Secretion
14%
Thiazolidinediones
13%
Palmitate
11%
Hemoglobin A1c (HbA1c)
11%
Dipeptidyl peptidase-4 (DPP-4)
11%
Type 2 Diabetes Prevention
11%
Dipeptidyl peptidase-IV (DPP-IV)
10%
Diabetes Management
10%
Hypoglycemia
10%
Weight Loss
9%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
9%
Antidiabetic Drug
8%
Clinical Trials
8%
1 Receptor
8%
Peroxisome Proliferator-activated Receptor
8%
Diabetic Mice
8%
Placebo
8%
Glucose Uptake
8%
Monotherapy
8%
Rosiglitazone
7%
Amides
7%
Fatty Acids
7%
Insulin Action
7%
Glucagon
7%
Receptor Agonist
7%
Islet
7%
Plasma Glucose
7%
B Cells
6%
Monocytes
6%
Sulfonylurea
6%
Skeletal muscle
6%
Blood Glucose
6%
Human Islets
6%
Vascular Complications
6%
Pharmacology, Toxicology and Pharmaceutical Science
Maturity Onset Diabetes of the Young
74%
Glucose
69%
Insulin
63%
Metformin
27%
Gastric Inhibitory Polypeptide
19%
Insulin Resistance
17%
Ob/Ob Mouse
16%
Hyperglycemia
14%
Dapagliflozin
13%
Antidiabetic Agent
13%
Placebo
11%
Diabetes Mellitus
10%
Hypoglycemia
10%
Peptide
9%
Diabetic Obesity
9%
Hemoglobin A1c
9%
Monotherapy
9%
Clinical Trial
8%
Dipeptidyl Peptidase IV Inhibitor
8%
Glucagon-Like Peptide-1
8%
Thiazolidinedione
8%
Glucagon
8%
Fatty Acid
7%
Incretin
7%
Pharmacotherapy
7%
sodium glucose cotransporter-2 inhibitors
6%
Sodium Glucose Cotransporter 2 Inhibitor
6%
Receptor
6%
Rat
5%
Palmitic Acid
5%
Oral Antidiabetic Agent
5%
Sibutramine
5%
Sulfonylurea
5%
Leptin
5%
Medicine and Dentistry
Maturity Onset Diabetes of the Young
61%
Glycon
47%
Insulin
38%
Diabetes
33%
Glucose
29%
Glycemic Control
20%
Insulin Resistance
14%
Diabetes Mellitus
12%
Gastric Inhibitory Polypeptide
11%
Hyperglycemia
10%
Insulin Release
10%
Antidiabetic Agent
10%
Patient with Type 2 Diabetes
8%
Hypoglycemia
8%
Blood Glucose
8%
Ob/Ob Mouse
7%
Glucagon Like Peptide 1
7%
Antidiabetic Activity
6%
Receptor
6%
Incretin
6%
Peptide
5%
Drug Therapy
5%
Oral Antidiabetic Agent
5%
Clinical Trial
5%
Glycemic
5%
Dapagliflozin
5%